Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Montanide ISA-51/peptide 946-tetanus peptide conjugate melanoma vaccine

Known as: ISA-51/p946-Tet p, ISA-51/p946/Tet p, Montanide ISA-51/peptide 946 melanoma vaccine/tetanus peptide melanoma vaccine 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Slow-release delivery has great potential for specifically targeting immune-modulating agents into the tumor-draining area. In… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2011
2011
A central goal in vaccinology is the induction of high and sustained Ab responses. Protein-in-adjuvant formulations are commonly… Expand
Is this relevant?
2006
2006
BACKGROUND A prophylactic vaccine for hepatitis C virus (HCV) requires generation of strong humoral as well as CD4(+) and CD8… Expand
Is this relevant?
2004
2004
Previous studies in small groups of patients suggested that immunization of melanoma patients with peptide epitopes recognized by… Expand
  • table 1
  • table 1
  • table 2
  • table 3
  • table 3
Is this relevant?
2004
2004
Introduction: The UBITh ® -VP1 synthetic peptide-based vaccine for FMDV O, formulated as a water-in-oil emulsion, was evaluated… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
1999
1999
In a previous work we selected montanide ISA720 (M-ISA720) among different adjuvants for the vaccination with a V3 loop based… Expand
Is this relevant?